Research topics
Biomarker research articles covering molecular signals, prediction tools, and measures used to study Crohn's disease, ulcerative colitis, or broader IBD.
Page 4 of 8 · 360 articles
If blood bile acid patterns are reproducibly different in IBD and track with disease activity, they could become noninvasive biomarkers to help diagnose IBD or monitor flares. That would be useful for patients and...
Knowing which symptoms and non-invasive biomarkers most strongly associate with UC can help patients and clinicians decide who should be prioritized for diagnostic endoscopy and for monitoring disease activity.
Non-invasive, portable tests that can track inflammation more frequently could help patients and clinicians monitor disease activity between clinic visits and guide treatment decisions without repeated invasive...
People with IBD are at higher risk for colorectal cancer; identifying stromal genes that track inflammation-driven EMT could help researchers find biomarkers or targets that explain how chronic inflammation promotes...
A blood test (serum REG3α) may help identify people at higher risk of developing complicated Crohn's disease years before diagnosis and predict progression in established disease, which could inform monitoring or early...
Finding reliable blood biomarkers for ulcerative colitis activity could make monitoring disease flares easier and less dependent on invasive tests. NGAL and S100A12 rising with active disease suggests they might help...
Protease and serpin activity affect the gut barrier, immunity, and microbial ecology—processes central to IBD. Integrating these pathways could help identify biomarkers or targets that explain why IBD varies between...
The study expands the map of gut archaea and identifies archaeal species associated with IBD/UC, suggesting new microbial biomarkers and potential microbe–microbe interactions that might influence inflammation.
If you have IBD, emerging forms of regulated cell death may help explain ongoing intestinal inflammation and could become targets for future tests or treatments. This review highlights multiple RCD pathways linked to...
Treatment resistance is a major hurdle in IBD care; this review maps how microbiota, immune imbalance, and epigenetics may work together to cause drug-resistant disease and suggests potential precision strategies that...
This narrative review surveys novel biomarkers and therapeutic strategies for adult IBD, topics that could affect diagnosis, monitoring, and future treatment options for people with Crohn's disease or ulcerative colitis.
This observational study aims to link nutritional status and the dietary inflammatory potential to IBD activity and to test whether simple blood-derived inflammatory indices can serve as noninvasive markers of disease...
Researchers are investigating circRNAs as potential biomarkers and therapeutic targets in IBD because they may help explain disease mechanisms and lead to better diagnostics or treatments in the future.
The study identifies distinct fecal bile acid signatures in CRC versus UC that might help develop noninvasive tests to distinguish malignancy from chronic inflammatory disease of the colon.
The study provides a more rigorous, leakage-free machine-learning analysis of a major IBD microbiome cohort and proposes reproducible microbial and metabolic pathway candidates that could eventually help IBD diagnosis or...
Distinguishing acute infectious gastroenteritis from new‑onset IBD can be clinically challenging. Faecal biomarkers that help tell these apart could speed correct diagnosis and treatment and avoid unnecessary...
Patients with UC who appear healed on endoscopy can still relapse; a biopsy-based model could help separate lower- and higher-risk patients and guide monitoring or research enrollment.
FABP2 is presented as a sensitive biomarker of intestinal mucosal injury and a possible contributor to IBD mechanisms; if validated, it could improve disease monitoring and suggest new therapeutic targets.
The review lays out a multidimensional precision-care model that could help make IBD treatment more personalized, reduce unnecessary continuous medication, and use biomarker and technology-driven adjustments to manage...
The work searches for shared blood-based gene signatures and biomarkers across HLA-B27–linked diseases (including Crohn’s disease and ulcerative colitis), which could point to common mechanisms or cross-disease...
Researchers identified molecular features of a proposed “ferro‑aging” state in UC and nominated CHST15 and MSN as biomarkers, which could help understand disease biology and point to new experimental targets for therapy...
The review summarizes how extracellular vesicles (EVs) shape immune responses and barrier repair in the gut and discusses their potential as accessible biomarkers and as vehicles for precise IBD therapies — topics that...
A wearable sensor that reliably measures inflammation markers (CRP and calprotectin) from sweat could make inflammation monitoring less invasive and more frequent for people with IBD, potentially helping detect flares...
The review proposes a low-cost, non-immunosuppressive adjunctive strategy targeting the gut microbiome and luminal metabolism to help maintain remission in UC, an area of strong patient interest but limited clinical...
This trial tests a new oral live biotherapeutic designed to affect inflammation and the gut microbiome in Crohn’s disease. Early‑phase safety and pharmacodynamic results could influence future development of...
If you have overweight or obesity, this study suggests measurable blood proteins linked to inflammation may be associated with higher future risk of ulcerative colitis. Identifying such markers could help research on...
A strategic, pediatric-focused research agenda helps target studies where children with IBD and related conditions most need better diagnostics, biomarkers, and treatments. Prioritizing multi-center registries and...
Non-invasive, inexpensive blood-derived ratios could offer easier, more frequent assessment of IBD activity than repeat endoscopy. This study evaluates several such ratios (CAR, PAR, NLR, FAR, Hb/CRP) against clinical...
Researchers are exploring ferroptosis as a double-edged mechanism: preventing it may protect healthy gut lining in IBD, while inducing it might help treat colorectal cancer. Advances could lead to new biomarkers or...
Non-invasive biomarkers can help detect and monitor IBD activity, distinguish IBD from other GI conditions, and potentially predict relapse—tools that may reduce need for invasive tests.
Researchers present a small platelet-related gene signature (TRIM22, TIMP1, RAC2) that may help understand UC biology and point toward blood-based biomarkers. If validated further, such markers might aid noninvasive...
Biomarker discordance is common in treat-to-target IBD care; understanding which tests reflect local gut inflammation versus systemic response can help avoid unnecessary treatment changes and guide targeted...
Fucosylation appears to influence intestinal barrier function, host–microbiota interactions, and immune responses — processes central to IBD pathogenesis. If validated, fucosylation-related biomarkers or therapies could...
Basal crypt dysplasia is easy to miss but linked to higher risk of advanced colorectal neoplasia in longstanding IBD. Improved recognition and use of p53 immunohistochemistry or complementary biomarkers could affect...
TL1A-DR3 is implicated in both inflammation and fibrosis in IBD, so targeting it could address active disease and reduce fibrotic complications that lead to strictures. New TL1A-blocking antibodies are already in...
Early-phase mechanistic trials test how a new drug affects disease biology and safety; results can help decide whether larger trials should follow.
If validated, an imaging-derived adipose heterogeneity biomarker could help predict who will lose response to infliximab after induction, potentially guiding earlier treatment decisions and personalized monitoring for...
The study points to three bile-acid–related genes that may be linked to inflammation in ulcerative colitis and could serve as biomarkers or targets for future research into disease mechanisms and patient stratification.
Treg/Th17 balance is a central immune mechanism implicated in IBD pathogenesis; understanding how microbes, metabolites, and tissue context control that balance could inform new biomarkers and targeted therapies.
This review summarizes human evidence that pesticides in the diet could affect the gut microbiome and may be linked to gastrointestinal outcomes including IBD; strongest consistent signals were for organochlorine...
The work aims to predict relapse and personalize herbal maintenance dosing for UC, which matters because better risk stratification and tailored management could reduce relapses and avoid unnecessary treatment changes.
Blood biomarkers that predict vedolizumab response could help patients and clinicians choose the most effective therapy sooner and avoid ineffective treatments. The study suggests LRG and MCP‑1 may differentiate...
IBD-U means no clear Crohn’s or ulcerative colitis diagnosis yet — that uncertainty can affect treatment decisions and follow-up. The review highlights tests that may help clarify diagnosis and stresses that many...
The paper identifies a gut microbiome–driven pathway (flagellin → TLR5 → IL-15 → ARA) that might link intestinal microbial changes to systemic inflammation seen in long COVID and other immune-mediated diseases,...
The report describes a novel small-molecule inhibitor (IMYX-3) targeting RAB27A to reduce neutrophil-mediated damage in ulcerative colitis models, which could point to a new therapeutic approach if later validated in...
If validated, IGFBP5 or its downstream pathway could help predict who will not respond to anti-TNF therapy and point to new targets to overcome resistance.
Quantitative, rapid stool tests could make it easier to track intestinal inflammation without central lab delays. If translated to clinical use, SERS-enhanced lateral-flow assays might allow more frequent, point-of-care...
The study points to serum protein panels and tissue expression of glypican-6 (GPC6) as potential tools to diagnose or predict intestinal strictures in Crohn disease, which could help detect fibrosis earlier and guide...
